Ferro, Charles J.
Mark, Patrick B.
Kanbay, Mehmet
Sarafidis, Pantelis
Heine, Gunnar H.
Rossignol, Patrick
Massy, Ziad A.
Mallamaci, Francesca
Valdivielso, Jose M.
Malyszko, Jolanta
Verhaar, Marianne C.
Ekart, Robert
Vanholder, Raymond
London, Gerard
Ortiz, Alberto http://orcid.org/0000-0002-9805-9523
Zoccali, Carmine
Article History
First Online: 25 October 2018
Change Date: 11 December 2018
Change Type: Correction
Change Details: In the acknowledgements section of this article as originally published, information on the authors’ roles as EURECAm members is missing. The correct acknowledgement is as follows: “This Review was planned as part of the activity of the European Renal and Cardiovascular Medicine working (EURECAm) group and all authors are EURECAm members. A.O.’s work was supported by Spanish Government ISCIII FEDER funds (PI16/02057, ISCIII-RETIC REDinREN RD16/0009) and Community of Madrid (B2017/BMD-3686 CIFRA2-CM). P.R.’s work is supported by a public grant overseen by the French National Research Agency (ANR) as part of the second “Investissements d’Avenir” program FIGHT-HF (reference: ANR-15-RHU-0004) and by the French PIA project “Lorraine Université d’Excellence”, reference ANR-15-IDEX-04-LUE.” The omission has been corrected in the PDF and HTML versions of the article.
Competing interests
: A.O. is a consultant for Sanofi Genzyme and has received speaker fees from Amgen. Z.A.M. has received grants for CKD REIN and other research projects from Amgen, Baxter, Fresenius Medical Care, GlaxoSmithKline, Merck Sharp and Dohme-Chibret, Sanofi-Genzyme, Lilly, Otsuka and the French government, as well as fees and grants to charities from Amgen and Daichii. P.R. has consulted for Novartis, Relypsa, AstraZeneca, Grünenthal, Stealth Peptides, Fresenius, Idorsia, Vifor Fresenius Medical Care Renal Pharma, Vifor and CTMA, has received lecture fees from Bayer and CVRx and is a cofounder of CardioRenal. The other authors declare no competing interests.